NYSE:QGEN - Qiagen Stock Price, Forecast & News

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Qiagen NV (NYSE:QGEN) released its quarterly earnings data on Wednesday, October, 30th. The company reported $0.36 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.01. The company had revenue of $382.70 million for the quarter, compared to the consensus estimate of $382.98 million. Qiagen had a positive return on equity of 12.24% and a negative net margin of 1.68%. The company's quarterly revenue was up 1.3% compared to the same quarter last year. During the same period last year, the business posted $0.35 EPS. View Qiagen's Earnings History.

Qiagen is scheduled to release their next quarterly earnings announcement on Monday, February 3rd 2020. View Earnings Estimates for Qiagen.

Qiagen issued an update on its FY19 earnings guidance on Wednesday, October, 30th. The company provided earnings per share (EPS) guidance of $1.43-1.44 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.38. The company issued revenue guidance of ~$1.56 billion, compared to the consensus revenue estimate of $1.53 billion.

17 brokers have issued twelve-month price objectives for Qiagen's stock. Their forecasts range from $31.00 to $48.00. On average, they expect Qiagen's stock price to reach $37.38 in the next twelve months. This suggests that the stock has a possible downside of 9.2%. View Analyst Price Targets for Qiagen.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 8 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Qiagen.

Media headlines about QGEN stock have been trending neutral on Friday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Qiagen earned a news impact score of 0.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Qiagen.

Qiagen saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 4,010,000 shares, an increase of 13.3% from the September 15th total of 3,540,000 shares. Based on an average daily volume of 1,390,000 shares, the short-interest ratio is presently 2.9 days. Approximately 1.9% of the company's stock are sold short. View Qiagen's Current Options Chain.

Some companies that are related to Qiagen include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), bluebird bio (BLUE), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP) and Allogene Therapeutics (ALLO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include Netflix (NFLX), Gilead Sciences (GILD), NVIDIA (NVDA), Boeing (BA), Twitter (TWTR), Cisco Systems (CSCO), QUALCOMM (QCOM), Activision Blizzard (ATVI), Exelixis (EXEL) and Starbucks (SBUX).

Qiagen's stock is owned by a number of of institutional and retail investors. Top institutional investors include Massachusetts Financial Services Co. MA (5.55%), Hardman Johnston Global Advisors LLC (1.77%), State Street Corp (0.96%), First Trust Advisors LP (0.68%), Sycomore Asset Management (0.63%) and Parametric Portfolio Associates LLC (0.43%).

QGEN stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Assenagon Asset Management S.A., Hardman Johnston Global Advisors LLC, Parametric Portfolio Associates LLC, Man Group plc, Exane Asset Management, Zurcher Kantonalbank Zurich Cantonalbank and Squarepoint Ops LLC.

QGEN stock was purchased by a variety of institutional investors in the last quarter, including Sycomore Asset Management, Massachusetts Financial Services Co. MA, Phoenix Holdings Ltd., Point72 Asset Management L.P., Fisher Asset Management LLC, SG Americas Securities LLC, Sector Gamma AS and Russell Investments Group Ltd..

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of QGEN stock can currently be purchased for approximately $41.16.

Qiagen has a market capitalization of $9.28 billion and generates $1.50 billion in revenue each year. The company earns $190.38 million in net income (profit) each year or $1.34 on an earnings per share basis. Qiagen employs 4,952 workers across the globe.View Additional Information About Qiagen.

The official website for Qiagen is http://www.qiagen.com/.

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912 PL. The company can be reached via phone at 31-77-355-6600 or via email at [email protected]